These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8792397)

  • 1. The effects of recombinant human erythropoietin on growth and nutritional status.
    Jabs K
    Pediatr Nephrol; 1996 Jun; 10(3):324-7. PubMed ID: 8792397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin therapy in children on dialysis.
    Jabs K; Harmon WE
    Adv Ren Replace Ther; 1996 Jan; 3(1):24-36. PubMed ID: 8620365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized prospective comparison between erythropoietin and androgens in CAPD patients.
    Navarro JF; Mora C; Macía M; García J
    Kidney Int; 2002 Apr; 61(4):1537-44. PubMed ID: 11918762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of recombinant human erythropoietin (rHuEPO) on nutritional status of hemodialysis patients: investigation of direct anabolic effects of rHuEPO.
    Usuba T; Kuno T; Higuchi T; Kikuchi F; Nagura Y; Kanmatsuse K; Takahashi S
    Nihon Jinzo Gakkai Shi; 1994 Nov; 36(11):1288-95. PubMed ID: 7853762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric uses of recombinant human erythropoietin: the outlook in 1991.
    Alexander SR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):42-53. PubMed ID: 1928079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):343-54. PubMed ID: 26889660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin-induced changes in protein nutrition: quantitative assessment by urea kinetic modeling analysis.
    Canaud B; Bouloux C; Rivory JP; Taib J; Garred LJ; Florence P; Mion C
    Blood Purif; 1990; 8(5):301-8. PubMed ID: 2091690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children.
    Varan A; Büyükpamukçu M; Kutluk T; Akyüz C
    Pediatrics; 1999 Feb; 103(2):E16. PubMed ID: 9925862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Biochimie; 2016 Jun; 125():150-62. PubMed ID: 27039028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group.
    Am J Kidney Dis; 1991 Jul; 18(1):50-9. PubMed ID: 2063855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the correction of anemia with recombinant human erythropoietin on growth of children treated with CAPD.
    Stefanidis CJ; Koulieri A; Siapera D; Kapogiannis A; Mitsioni A; Michelis K
    Adv Perit Dial; 1992; 8():460-3. PubMed ID: 1361848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
    Allegra V; Martimbianco L; Vasile A
    Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.
    Case DC; Bukowski RM; Carey RW; Fishkin EH; Henry DH; Jacobson RJ; Jones SE; Keller AM; Kugler JW; Nichols CR
    J Natl Cancer Inst; 1993 May; 85(10):801-6. PubMed ID: 8487324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.
    Jungers P; Choukroun G; Oualim Z; Robino C; Nguyen AT; Man NK
    Nephrol Dial Transplant; 2001 Feb; 16(2):307-12. PubMed ID: 11158405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin and the anemia of chronic diseases.
    De Marchi S; Pirisi M; Ferraccioli GF
    Clin Exp Rheumatol; 1993; 11(4):429-44. PubMed ID: 8403591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients.
    Hung SC; Tung TY; Yang CS; Tarng DC
    Am J Kidney Dis; 2005 Jun; 45(6):1073-83. PubMed ID: 15957137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin and sexual dysfunction.
    Lawrence IG; Price DE; Howlett TA; Harris KP; Feehally J; Walls J
    Nephrol Dial Transplant; 1997 Apr; 12(4):741-7. PubMed ID: 9141005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron management during treatment with recombinant human erythropoietin in chronic renal failure.
    Watson A
    J Clin Pharmacol; 1993 Dec; 33(12):1134-8. PubMed ID: 8126248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
    Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
    Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.